Why the study?
Does the extent of histologic necrosis after neoadjuvant chemotherapy predict local recurrence and overall survival in patients with soft tissue sarcomas of the extremities?
Does the extent of histologic necrosis after neoadjuvant chemotherapy predict local recurrence and overall survival in patients with soft tissue sarcomas of the extremities?
The amount of histologic tissue necrosis following neoadjuvant chemotherapy does not predict local recurrence or overall survival in patients with soft tissue sarcomas of the extremities.
Answers are grounded in this paper and cite their sources.
Necrosis extent should not inform prognosis in extremity soft tissue sarcoma; challenges its validity as a surrogate endpoint.
Neoadjuvant chemotherapy for treatment of soft tissue sarcomas is controversial, and the correlation between local recurrence and survival is unclear. Histologic necrosis is a well-documented predictor of survival in patients with malignant bone tumors; however, the association is unknown in patients with soft tissue sarcomas. We assessed the prognostic significance of tumor necrosis for treatment of soft tissue sarcomas. We retrospectively collected data from 82 patients who received neoadjuvant chemotherapy for treatment of soft tissue sarcomas of the extremities. Patients had wide resections if tumors were high-grade, deep to the investing fascia, and had clear margins. We quantified the amount of necrosis and analyzed the relationship with local recurrence and overall survival. At an average followup of 65 months (range, 24-154 months), the 5-year local recurrence rates for patients with less than 95% and 95% or greater necrosis were 20% and 33%, respectively. The overall 5-year survivorship rates for patients with less than 95% necrosis and 95% or greater necrosis were 82% and 78%, respectively. There was no difference in recurrence-free survival or overall patient survival based on the amount of histologic necrosis. Tissue necrosis from neoadjuvant chemotherapy does not seem to predict outcome in soft tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Menendez et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: